From Chemistry to Clinic: Amorphous Solid-State Modification Strategies for Oral Azole Antifungals

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Solid-State Chemistry

Background:

• Azole antifungals are crucial for mycoses but face challenges with oral formulation adherence and bioavailability.
• Existing crystalline formulations limit aqueous solubility, while amorphous systems present stability and hygroscopicity issues.
• Need for advanced oral formulations to address antifungal resistance and treatment failures.

Purpose of the Study:

• To explore supramolecular solid-state design for azole antifungals, focusing on noncrystalline forms.
• To evaluate eutectic mixtures as a promising formulation approach for improving azole oral bioavailability.
• To consolidate knowledge on azole solid-state chemistry and highlight limitations of current strategies.

Main Methods:

• Review of current literature on azole solid-state chemistry and formulation strategies.
• Analysis of the properties and potential of amorphous, coamorphous, and eutectic systems.
• Evaluation of eutectic mixtures as an alternative to traditional crystalline and amorphous forms.

Main Results:

• Eutectic systems offer enhanced solubility and bioavailability, bridging the gap between amorphous and crystalline forms.
• They provide improved solubility without the need for polymeric stabilizers common in amorphous formulations.
• The pharmaceutical potential of eutectic mixtures for azoles, particularly BCS II compounds, is significantly underexplored.

Conclusions:

• Eutectic mixtures represent a viable and impactful strategy for developing next-generation azole oral formulations.
• This approach can overcome limitations of current azole products, leading to improved therapeutic performance.
• Intentional eutectic design is positioned as a key pathway for enhancing azole oral bioavailability.